Page last updated: 2024-09-05

deferasirox and Neuroectodermal Tumors, Primitive, Peripheral

deferasirox has been researched along with Neuroectodermal Tumors, Primitive, Peripheral in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Codd, R; Groebler, LK; Kalinowski, DS; Liu, J; Obando, D; Richardson, DR; Schipanski, LG; Witting, PK	1
Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C	1

Other Studies

2 other study(ies) available for deferasirox and Neuroectodermal Tumors, Primitive, Peripheral

Article	Year
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Chelating Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deferoxamine; Dogs; Ferric Compounds; Humans; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Iron Overload; Kidney; Models, Molecular; Molecular Structure; Neuroectodermal Tumors, Primitive, Peripheral; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Transferrin	2010
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Molecular pharmacology, 2013, Volume: 83, Issue:1 Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc	2013

Article

Year

Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.

Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Chelating Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deferoxamine; Dogs; Ferric Compounds; Humans; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Iron Overload; Kidney; Models, Molecular; Molecular Structure; Neuroectodermal Tumors, Primitive, Peripheral; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Transferrin

2010

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

Molecular pharmacology, 2013, Volume: 83, Issue:1

Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc

2013